{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:06:30Z","timestamp":1791331590946,"version":"4.3.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T00:00:00Z","timestamp":1447027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/leu.2015.316","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T02:40:55Z","timestamp":1447900855000},"page":"833-843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"30","author":[{"given":"S-S","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B Y","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K R","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Chiorazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,9]]},"reference":[{"key":"BFleu2015316_CR1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/eji.201344030","volume":"44","author":"J Wang","year":"2014","unstructured":"Wang J, Lau K-Y, Jung J, Ravindran P, Barrat FJ . Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells. Eur J Immunol 2014; 44: 1130\u20131136.","journal-title":"Eur J Immunol"},{"key":"BFleu2015316_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP . Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer 2014; 14: 219\u2013232.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2015316_CR3","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","volume":"94","author":"JA Burger","year":"1999","unstructured":"Burger JA, Burger M, Kipps TJ . Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999; 94: 3658\u20133667.","journal-title":"Blood"},{"key":"BFleu2015316_CR4","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/sj.leu.2401602","volume":"13","author":"R Mohle","year":"1999","unstructured":"Mohle R, Failenschmid C, Bautz F, Kanz L . Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 1999; 13: 1954\u20131959.","journal-title":"Leukemia"},{"key":"BFleu2015316_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s00277-003-0679-0","volume":"82","author":"J Barretina","year":"2003","unstructured":"Barretina J, Junca J, Llano A, Gutierrez A, Flores A, Blanco J et al. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol 2003; 82: 500\u2013505.","journal-title":"Ann Hematol"},{"key":"BFleu2015316_CR6","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.leukres.2010.10.022","volume":"35","author":"A Majid","year":"2011","unstructured":"Majid A, Lin TT, Best G, Fishlock K, Hewamana S, Pratt G et al. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res 2011; 35: 750\u2013756.","journal-title":"Leuk Res"},{"key":"BFleu2015316_CR7","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MF de Rooij","year":"2012","unstructured":"de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590\u20132594.","journal-title":"Blood"},{"key":"BFleu2015316_CR8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1084\/jem.20011866","volume":"198","author":"M Spaargaren","year":"2003","unstructured":"Spaargaren M, Beuling EA, Rurup ML, Meijer HP, Klok MD, Middendorp S et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med 2003; 198: 1539\u20131550.","journal-title":"J Exp Med"},{"key":"BFleu2015316_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","volume":"26","author":"DJ de Gorter","year":"2007","unstructured":"de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007; 26: 93\u2013104.","journal-title":"Immunity"},{"key":"BFleu2015316_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2013; 369: 32\u201342.","journal-title":"N Engl J Med"},{"key":"BFleu2015316_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. N Engl J Med 2014; 371: 213\u2013223.","journal-title":"N Engl J Med"},{"key":"BFleu2015316_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1084\/jem.189.9.1461","volume":"189","author":"R Guinamard","year":"1999","unstructured":"Guinamard R, Signoret N, Ishiai M, Marsh M, Kurosaki T, Ravetch JV . B cell antigen receptor engagement inhibits stromal cell-derived factor (SDF)-1alpha chemotaxis and promotes protein kinase C (PKC)-induced internalization of CXCR4. J Exp Med 1999; 189: 1461\u20131466.","journal-title":"J Exp Med"},{"key":"BFleu2015316_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.imbio.2005.12.003","volume":"211","author":"E Palmesino","year":"2006","unstructured":"Palmesino E, Moepps B, Gierschik P, Thelen M . Differences in CXCR4-mediated signaling in B cells. Immunobiology 2006; 211: 377\u2013389.","journal-title":"Immunobiology"},{"key":"BFleu2015316_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ceb.2013.11.011","volume":"27","author":"A Marchese","year":"2014","unstructured":"Marchese A . Endocytic trafficking of chemokine receptors. Curr Opin Cell Biol 2014; 27: 72\u201377.","journal-title":"Curr Opin Cell Biol"},{"key":"BFleu2015316_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/27454","volume":"395","author":"Y Jiang","year":"1998","unstructured":"Jiang Y, Ma W, Wan Y, Kozasa T, Hattori S, Huang XY . The G protein G alpha12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH\/BM domain. Nature 1998; 395: 808\u2013813.","journal-title":"Nature"},{"key":"BFleu2015316_CR16","doi-asserted-by":"publisher","first-page":"11256","DOI":"10.1073\/pnas.91.23.11256","volume":"91","author":"S Tsukada","year":"1994","unstructured":"Tsukada S, Simon MI, Witte ON, Katz A . Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. Proc Natl Acad Sci USA 1994; 91: 11256\u201311260.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015316_CR17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S, Chen S-S, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182\u20131189.","journal-title":"Blood"},{"key":"BFleu2015316_CR18","doi-asserted-by":"publisher","first-page":"12530","DOI":"10.1073\/pnas.91.26.12530","volume":"91","author":"L Virgilio","year":"1994","unstructured":"Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 12530\u201312534.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015316_CR19","doi-asserted-by":"publisher","first-page":"E1500","DOI":"10.1073\/pnas.1300616110","volume":"110","author":"SS Chen","year":"2013","unstructured":"Chen SS, Batliwalla F, Holodick NE, Yan XJ, Yancopoulos S, Croce CM et al. Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling. Proc Natl Acad Sci USA 2013; 110: E1500\u2013E1507.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015316_CR20","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075\u201313080.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015316_CR21","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1158\/1535-7163.MCT-13-0575-T","volume":"13","author":"S Decker","year":"2014","unstructured":"Decker S, Finter J, Forde AJ, Kissel S, Schwaller J, Mack TS et al. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2\/3) and CXCR4-mediated microenvironmental interactions (PIM1). Mol Cancer Ther 2014; 13: 1231\u20131245.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2015316_CR22","doi-asserted-by":"publisher","first-page":"7805","DOI":"10.1074\/jbc.M109.091173","volume":"285","author":"JM Busillo","year":"2010","unstructured":"Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL . Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 2010; 285: 7805\u20137817.","journal-title":"J Biol Chem"},{"key":"BFleu2015316_CR23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4049\/jimmunol.156.2.549","volume":"156","author":"D Wingett","year":"1996","unstructured":"Wingett D, Long A, Kelleher D, Magnuson NS . pim-1 proto-oncogene expression in anti-CD3-mediated T cell activation is associated with protein kinase C activation and is independent of Raf-1. J Immunol 1996; 156: 549\u2013557.","journal-title":"J Immunol"},{"key":"BFleu2015316_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nri3487","volume":"13","author":"RC Rickert","year":"2013","unstructured":"Rickert RC . New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol 2013; 13: 578\u2013591.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2015316_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S0014-5793(99)01424-6","volume":"461","author":"FJ Johannes","year":"1999","unstructured":"Johannes FJ, Hausser A, Storz P, Truckenmuller L, Link G, Kawakami T et al. Bruton's tyrosine kinase (Btk) associates with protein kinase C mu. FEBS Lett 1999; 461: 68\u201372.","journal-title":"FEBS Lett"},{"key":"BFleu2015316_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1074-7613(00)80261-7","volume":"5","author":"SP Sidorenko","year":"1996","unstructured":"Sidorenko SP, Law CL, Klaus SJ, Chandran KA, Takata M, Kurosaki T et al. Protein kinase C mu (PKC mu) associates with the B cell antigen receptor complex and regulates lymphocyte signaling. Immunity 1996; 5: 353\u2013363.","journal-title":"Immunity"},{"key":"BFleu2015316_CR27","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1182\/blood-2009-05-219634","volume":"114","author":"C Calissano","year":"2009","unstructured":"Calissano C, Damle RN, Hayes G, Murphy EJ, Hellerstein MK, Moreno C et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009; 114: 4832\u20134842.","journal-title":"Blood"},{"key":"BFleu2015316_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-012-0147-9","volume":"8","author":"JR Brown","year":"2013","unstructured":"Brown JR . Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials. Curr Hematol Malig Rep 2013; 8: 1\u20136.","journal-title":"Curr Hematol Malig Rep"},{"key":"BFleu2015316_CR29","doi-asserted-by":"publisher","first-page":"11713","DOI":"10.1073\/pnas.0604564103","volume":"103","author":"XJ Yan","year":"2006","unstructured":"Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103: 11713\u201311718.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015316_CR30","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1073\/pnas.96.5.2262","volume":"96","author":"KJ Seidl","year":"1999","unstructured":"Seidl KJ, Wilshire JA, MacKenzie JD, Kantor AB, Herzenberg LA, Herzenberg LA . Predominant VH genes expressed in innate antibodies are associated with distinctive antigen-binding sites. Proc Natl Acad Sci USA 1999; 96: 2262\u20132267.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015316_CR31","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1182\/blood-2008-06-162024","volume":"112","author":"CC Chu","year":"2008","unstructured":"Chu CC, Catera R, Hatzi K, Yan XJ, Zhang L, Wang XB et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008; 112: 5122\u20135129.","journal-title":"Blood"},{"key":"BFleu2015316_CR32","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood-2009-09-244251","volume":"115","author":"CC Chu","year":"2010","unstructured":"Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, Damle RN et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010; 115: 3907\u20133915.","journal-title":"Blood"},{"key":"BFleu2015316_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1172\/JCI23409","volume":"115","author":"BT Messmer","year":"2005","unstructured":"Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755\u2013764.","journal-title":"J Clin Invest"},{"key":"BFleu2015316_CR34","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/leu.2014.122","volume":"28","author":"SEM Herman","year":"2014","unstructured":"Herman SEM, Niemann CU, Farooqui M, Jones J, Mustafa RZ, Lipsky A et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28: 2188\u20132196.","journal-title":"Leukemia"},{"key":"BFleu2015316_CR35","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","volume":"122","author":"BY Chang","year":"2013","unstructured":"Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013; 122: 2412\u20132424.","journal-title":"Blood"},{"key":"BFleu2015316_CR36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood.V124.21.78.78","volume":"124","author":"S Balasubramanian","year":"2014","unstructured":"Balasubramanian S, Schaffer M, Deraedt W, Davis C, Stepanchick E, Aquino R et al. Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL). Blood 2014; 124: 78.","journal-title":"Blood"},{"key":"BFleu2015316_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.13200","volume":"168","author":"Y Cao","year":"2014","unstructured":"Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88 -directed survival signalling in Waldenstrom macroglobulinaemia cells. Br J Haematol 2014; 168: 701\u2013707.","journal-title":"Br J Haematol"},{"key":"BFleu2015316_CR38","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/leu.2013.201","volume":"28","author":"L Brault","year":"2014","unstructured":"Brault L, Rovo A, Decker S, Dierks C, Tzankov A, Schwaller J . CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. Leukemia 2014; 28: 566\u2013576.","journal-title":"Leukemia"},{"key":"BFleu2015316_CR39","first-page":"23","volume":"26","author":"E Rozengurt","year":"2011","unstructured":"Rozengurt E . Protein kinase D signaling: multiple biological functions in health and disease. Physiology (Bethesda) 2011; 26: 23\u201333.","journal-title":"Physiology (Bethesda)"},{"key":"BFleu2015316_CR40","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1073\/pnas.050583597","volume":"97","author":"S Nisitani","year":"2000","unstructured":"Nisitani S, Satterthwaite AB, Akashi K, Weissman IL, Witte ON, Wahl MI . Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc Natl Acad Sci USA 2000; 97: 2737\u20132742.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015316_CR41","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ajh.23433","volume":"88","author":"R Bam","year":"2013","unstructured":"Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X et al. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Am J Hematol 2013; 88: 463\u2013471.","journal-title":"Am J Hematol"},{"key":"BFleu2015316_CR42","doi-asserted-by":"crossref","unstructured":"Burger JA, Li K, Keating M, Sivina M, Ferrajoli A, Jalayer A et al. Functional evidence from deuterated water labeling that the bruton tyrosine kinase inhibitor ibrutinib blocks leukemia cell proliferation and trafficking and promotes leukemia cell death in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. ASH Abstr 326 2014.","DOI":"10.1182\/blood.V124.21.326.326"},{"key":"BFleu2015316_CR43","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370: 2286\u20132294.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2015316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2015316","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2015316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T18:26:55Z","timestamp":1692124015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,9]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFleu2015316"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.316","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,9]]},"assertion":[{"value":"11 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BY Chang and S Chang as employees and\/or shareholders of Pharmacyclics, Inc. JA Burger and N Chiorazzi have received research funding from Pharmacyclics, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}